Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 75% confidence The document is an annual declaration under SEBI’s Substantial Acquisition Regulations confirming that the promoter/promoter group have not encumbered shares during the financial year. It is a mandatory regulatory disclosure submitted to stock exchanges rather than a financial report, management discussion, board change announcement, or transaction notice. It contains no financial statements or substantive data, but serves as a compliance filing. Therefore it falls under the generic Regulatory Filings category (RNS).
2026-06-05 English
Newspaper Publication- Q4 and FY 26 Financial Results
Report Publication Announcement Classification · 82% confidence The document is a compliance submission letter under SEBI Listing Regulations stating that newspaper advertisements of the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 have been approved by the Board and are attached. There are no actual financial statements or numerical results in the body itself—only a statement that the advertisements (i.e., the published summaries) are enclosed and available on the website. Under the “menu vs meal” rule, this is not the full results report (the meal) but an announcement that the report (via newspaper advertisement) has been published, which matches Report Publication Announcement (RPA).
2026-05-27 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 85% confidence The document is a compliance letter to stock exchanges under SEBI LODR Regulation 47 notifying the publication of audited standalone and consolidated financial results newspaper advertisements. It does not itself contain detailed financial statements or highlights but merely announces and encloses the ads. This is an announcement of report publication rather than the report itself.
2026-05-27 English
Please find enclosed Investor Presentation on Q4 & FY26 Results
Investor Presentation Classification · 93% confidence The document is addressed to stock exchanges and is titled “Investor Presentation – Q4 & FY26.” It contains slide content, strategic updates, financial highlights, charts, and forward-looking statements typical of a presentation to investors rather than an earnings press release or regulatory notice. It is well over 5,000 characters and contains the full presentation itself. Therefore, it is classified as an Investor Presentation.
2026-05-27 English
Please find enclosed press release
Earnings Release Classification · 90% confidence The document is a press release filed with stock exchanges summarizing key Q4 FY26 financial results (net profit, revenue growth) and other highlights (EBITDA, business updates, dividend proposal). It does not contain full financial statements or a detailed interim report structure; rather, it is the initial announcement of quarterly results. Therefore, it fits the definition of an Earnings Release. Q4 2026
2026-05-27 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release sent to the stock exchanges announcing Morepen Laboratories’ Q4 FY26 financial results – key metrics like revenue, net profit growth, business highlights, and a board‐proposed dividend. It is not a full quarterly report with detailed financial statements, nor just a regulatory notice; it is an initial earnings announcement. Therefore it best fits the Earnings Release category. Q4 2026
2026-05-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.